Arthur Dampier
Optometrist · Ridgeland, MSNPI 1649327545
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,384 of the $4,737 with a category attached, or 71.4%. 19 manufacturers reported payments, led by Eyevance Pharmaceuticals LLC at 32.5% of the total. Reporting peaked in 2021 at $2,189 and has fallen 79.3% since, to $453 in 2025. Among optometrist clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 123 payments — averaging $38.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eyevance Pharmaceuticals LLC$2K
- Alcon$1K
- Bausch & Lomb Americas Inc.$446
- Aerie Pharmaceuticals, Inc.$308
- Johnson & Johnson Vision Care, Inc.$256
- AbbVie$212
- plus $847 from 13 others
What the payments were for
- Speaking & faculty fees$1,32028%
- Food & beverage$3,38471%
- Education$331%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eyevance Pharmaceuticals LLC | 16 | $1,539 |
| Alcon | 31 | $1,130 |
| Bausch & Lomb Americas Inc. | 17 | $446 |
| Aerie Pharmaceuticals, Inc. | 8 | $308 |
| Johnson & Johnson Vision Care, Inc. | 6 | $256 |
| AbbVie(2 entities) | 12 | $212 |
| Glaukos Corporation | 3 | $161 |
| Shire North American Group Inc | 3 | $132 |
| Oyster Point Pharma, Inc. | 7 | $109 |
| Heidelberg Engineering, Inc. | 1 | $106 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $102 |
| Sun Pharmaceutical Industries Inc. | 4 | $64 |
| Optos, Inc. | 1 | $49 |
| Thea Pharma Inc. | 2 | $42 |
| Tarsus Pharmaceuticals, Inc. | 1 | $21 |
| Novartis | 1 | $17 |
| Biotissue Holdings Inc. | 1 | $16 |
| Coopervision Inc. | 1 | $15 |
| Kala Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Zerviate$1,328
- Rocklatan$208
- Precision7$132
- Acuvue$125
- XIIDRA$124
- MIEBO$123
- Pataday$120
- DAILIES$112
- VYZULTA$111
- iStent Trabecular Micro-Bypass Stent System$109
- iStent inject Trabecular Micro-Bypass Stent System$109
- Rhopressa$107
- Spectralis$106
How this compares
$4,737 in reported general payments places this provider in the 90th percentile of 372 optometrist providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 172 | $81,761 |
| RestasisCyclosporine | 74 | $64,245 |
| CombiganBrimonidine Tartrate/Timolol | 129 | $37,098 |
| XiidraLifitegrast | 39 | $34,898 |
| VyzultaLatanoprostene Bunod | 70 | $24,834 |
| RocklatanNetarsudil Mesylat/Latanoprost | 32 | $15,822 |
| RhopressaNetarsudil Mesylate | 17 | $5,245 |
| Cyclosporine | 16 | $4,629 |
| Brimonidine Tartrate | 52 | $2,187 |
| Latanoprost | 397 | $2,107 |
| Travoprost | 12 | $1,864 |
| Brinzolamide | 12 | $1,770 |
| Timolol Maleate | 62 | $1,003 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 53 | $894 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 49 | $562 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $212 | $183,104375 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $446 | $59,732109 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $308 | $21,06749 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 372 optometrist providers in Mississippi.
Other optometrist in Ridgeland
- Kristopher MayColdwater$229K
- Alyssa MabrySenatobia$66K
- Roya AttarJackson$19K
- Deandre CarrByram$9K
- Michael ObrienSouthaven$9K
- George MarchbanksGulfport$9K
- William ArnoldMadison$9K
- Ramonica LewisClinton$8K
- Megan LottHattiesburg$8K
- Hal HillMadison$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.